Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Use of Pioglitazone for the Prevention of Radiation-Induced Cognitive Dysfunction

RATIONALE: Pioglitazone hydrochloride may be effective treatment for cognitive dysfunction caused by radiation therapy.

PURPOSE: This phase I trial is studying the side effects and best dose of pioglitazone hydrochloride in preventing radiation-induced cognitive dysfunction in treating patients with brain tumors.

Study Overview

• Status: Completed
• Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Brain Neoplasms, Benign; Brain Neoplasms, Malignant; Malignant Meningioma
• Intervention / Treatment: Drug: pioglitazone; Drug: Pioglitazone

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate the tolerability and toxicity associated with two different dose regimens of pioglitazone administered orally as a cytoprotective agent against radiation-induced brain injury.

SECONDARY OBJECTIVE:

I. To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.

OUTLINE: Patients undergo fractionated external beam radiotherapy, 3-D conformal radiotherapy, or intensity-modulated radiotherapy. Patients receive oral pioglitazone hydrochloride once daily before for 1 week prior to brain irradiation, during and and continuing for 6 months after completion of radiation radiotherapy. After completion of study treatment, patients are followed periodically.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest University Health Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed brain tumors of the following types: Group 1: malignant brain tumors (glioblastoma multiforme, anaplastic gliomas, brain metastases, and other malignant brain tumors); or Group 2: low grade brain tumors (low grade gliomas, meningiomas, and other low grade brain tumors)
• All stages and grades of brain tumors are eligible
• Patients must have an ECOG performance status of 0-2
• Patients must have agreed to be treated with fractionated, external beam radiation treatment (EBRT) with either curative or palliative intent (the length of the radiation course must at least be ten fractions)
• Patients must have agreed to have CT and MR imaging for purposes of radiation treatment planning, radiation treatment monitoring, and/or radiation treatment evaluation
• Patients must have measurable disease and/or relevant anatomic features using Magnetic Resonance Imaging
• Prior therapies (cytotoxic, surgery, and radiation) are acceptable
• Use of steroids is acceptable when indicated
• Patients must be able to understand and willingly give informed written consent to participate
• Women of childbearing potential must not be pregnant or nursing and must use medically appropriate contraception if sexually active
• Patients must have a life expectancy of greater than 3 months
• Patients must be willing to comply with an oral treatment regimen and be able to swallow oral study tablets

Exclusion Criteria:

• History of allergic reactions to pioglitazone or any other member of the thiazolidinedione family
• Current diagnosis of diabetes as defined by fasting blood sugar > 125, treatment with anti-diabetic medications, or history of diabetes
• Patients who take insulin
• Patients who have NYHA class III or IV heart failure
• Patients who have elevated transaminases (AST or ALT > 2.5 times normal limit)
• Patients who have significantly impaired renal function (creatinine >= 1.5)
• Patients who are significantly anemic (hematocrit < 33% in men, or < 30% in women)
• Patients who have symptomatic edema (>= grade 2)
• Patients who are on medications that have been shown to have a drug interaction with pioglitazone: atorvastatin (doses > 80 mg/day), systemic anti-fungals, medications with significant CYP 3A4 inhibiting properties
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac, arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study if their pregnancy precludes radiation treatment because ionizing radiation used in radiation treatment is an agent with known potential for teratogenic or abortifacient effects
• Patients with psychiatric or social illnesses that may impair compliance with the trial requirements

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm I; Pioglitazone 22.5 mg once daily by mouth	Drug: pioglitazone; Pioglitazone 22.5 mg daily before, during and after radiation therapy.; Other Names: Actos
Experimental: Arm 2; Pioglitazone 45 mg once daily by mouth	Drug: Pioglitazone; Pioglitazone 45 mg by mouth daily before, during and after radiation therapy; Other Names: Actos

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Best tolerated dose of 2 different doses of orally administered pioglitazone	From first dose to 1 day after last dose of drug

Secondary Outcome Measures

Outcome Measure	Time Frame
Toxicities associated with both dose levels	From first dose to 1 day after last dose of drug
To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.	From first dose to 1 day after last dose of drug

Collaborators and Investigators

• Sponsor: Wake Forest University Health Sciences
• Investigators: Principal Investigator: Michael Chan, Wake Forest University Health Sciences

Study record dates

Study Major Dates

• Study Start: August 1, 2010
• Primary Completion (Actual): August 1, 2014
• Study Completion (Actual): August 1, 2014

Study Registration Dates

• First Submitted: June 25, 2010
• First Submitted That Met QC Criteria: June 25, 2010
• First Posted (Estimate): June 28, 2010

Study Record Updates

• Last Update Posted (Actual): August 1, 2018
• Last Update Submitted That Met QC Criteria: July 30, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Keywords: radiation therapy; brain tumor; memory problems; cognitive dysfunction; short term memory loss
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Neurocognitive Disorders; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Central Nervous System Neoplasms; Nervous System Neoplasms; Cognition Disorders; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Neoplasms; Glioblastoma; Cognitive Dysfunction; Brain Neoplasms; Astrocytoma; Meningioma; Hypoglycemic Agents; Physiological Effects of Drugs; Pioglitazone
• Other Study ID Numbers: IRB00014528; NCI-2009-01452 (Registry Identifier: CTRP); CCCWFU 97409 (Other Identifier: Wake Forest University Health Sciences)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No